To the Editor: In reference to the letter by Kennedy et al, reporting two patients who tested positive to human T-lymphotropic virus I/II (HTLV-I/HTLV-II) antibodies after administration of the intravenous immunoglobulin, Octagam (Octapharma Australia, Sydney, NSW),1 the Therapeutic Goods Administration (TGA) would submit that:
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- Albert Farrugia
- Office of Devices, Blood and Tissues, Therapeutic Goods Administration, Canberra, ACT.
Correspondence: albert.farrugia@health.gov.au
Online responses are no longer available. Please refer to our instructions for authors page for more information.